Dasatinib in Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Subjects Who Are Experiencing Clinical Benefit on Current START or CA180-039 Protocols: Long Term Safety and Efficacy Analysis
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine long term safety and tolerability with Dasatinib
Efficacy/ Safety and tolerability data assessed every 6 months
Yes
Bristol-Myers Squibb
Study Director
Bristol-Myers Squibb
United States: Food and Drug Administration
CA180-188
NCT00982488
October 2007
September 2014
Name | Location |
---|---|
UCLA School of Medicine | Los Angeles, California 900121973 |
Dana-Farber Cancer Institute | Boston, Massachusetts 02115 |
Oregon Health & Science University | Portland, Oregon 97201 |
University of Michigan Medical Center | Ann Arbor, Michigan 48104-0914 |
Wayne State University | Detroit, Michigan 48202 |
H. Lee Moffitt Cancer Center & Research Institute | Tampa, Florida 33612 |
University of Chicago | Chicago, Illinois 60637 |
Central Indiana Cancer Centers | Indianapolis, Indiana 46227 |
The Cancer Center at Hackensack University Medical Center | Hackensack, New Jersey 07601 |
The University Of Texas - M.D. Anderson Cancer Center | Houston, Texas 77030 |